论文部分内容阅读
目的:对接受经皮冠脉介入治疗(PCI)冠心病患者合并糖代谢异常的临床特征、治疗现状及护理要点进行探讨。方法:对我院2012年2月至2013年9月收治的110例冠心病PCI合并糖代谢异常患者的临床治疗以及护理进行回顾性分析。结果:110例冠心病PCI合并糖代谢异常患者中,合并代谢异常患者83例,接受PCI的冠心病患者代谢异常发病率为75.5%,通过给予患者口服二甲双胍和阿卡波糖治疗,并在患者住院期间给予科学的护理,110例患者治疗效果非常良好,均正常出院,108例患者及其患者家属对护理较为满意,护理满意度为98%。结论:对冠心病PCI合并糖代谢异常患者进行口服葡萄糖耐量实验(OGTT),能够有效的发现糖尿病早期患者,为患者口服二甲双胍以及阿卡波糖对糖耐量降低有着良好的控制作用,在住院期间对患者实施科学的护理,能够使患者尽快康复。
Objective: To investigate the clinical features, treatment status and nursing points of patients with coronary artery disease complicated with percutaneous coronary intervention (PCI). Methods: A retrospective analysis was performed on the clinical treatment and nursing care of 110 patients with PCI complicated with glycometabolism in our hospital from February 2012 to September 2013. Results: Of the 110 patients with coronary artery disease and PCI with abnormal glucose metabolism, 83 patients had metabolic abnormalities. The incidence of metabolic abnormalities in CHD patients receiving PCI was 75.5%. Patients were treated with metformin and acarbose orally. During the hospitalization, scientific nursing was given. The treatment effect of 110 patients was very good and all were discharged normally. The family members of 108 patients and their patients were satisfied with the nursing care, and the satisfaction rate of nursing was 98%. Conclusion: OGTT in patients with coronary artery disease complicated with PCI and glycometabolism abnormalities can effectively detect patients with early stage of diabetes, metformin and acarbose orally for patients with good control of impaired glucose tolerance. During hospitalization The implementation of scientific patient care, patients can recover as soon as possible.